The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Low LDL cholesterol,PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
Open accessAbstract
Objective To test the hypothesis that low density lipoprotein (LDL) cholesterol due to genetic variation in the genes responsible for LDL cholesterol metabolism and biosynthesis(PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), respectively) is associated with a high risk of Alzheimer’s disease, vascular dementia, any dementia, and Parkinson’s disease in the general population. Design Mendelian randomisation study. Setting Copenhagen General Population Study and Copenhagen City Heart Study. Participants 111 194 individuals from the Danish general population. Main outcome measures Risk of Alzheimer’s disease, vascular dementia, all dementia, and Parkinson’s disease. Results In observational analyses, the multifactorially adjusted hazard ratio for Parkinson’s disease in participants with an LDL cholesterol level <1.8 mmol/L versus ≥4.0 mmol/L was 1.70 (95% confidence interval 1.03 to 2.79), whereas the corresponding hazard ratios for Alzheimer’s disease, vascular dementia, or any dementia did not differ from 1.0. PCSK9 and HMGCR variants combined were associated with a 9.3% lower LDL cholesterol level. In genetic, causal analyses adjusted for age, sex, and year of birth, the risk ratios for a lifelong 1 mmol/L lower LDL cholesterol level were 0.57 (0.27 to 1.17) for Alzheimer’s disease, 0.81 (0.34 to 1.89) for vascular dementia, 0.66 (0.34 to 1.26) for any dementia, and 1.02 (0.26 to 4.00) for Parkinson’s disease. Summary level data from the International Genomics of Alzheimer’s Project using Egger Mendelian randomisation analysis gave a risk ratio for Alzheimer’s disease of 0.24 (0.02 to 2.79) for 26 PCSK9 and HMGCR variants, and of 0.64 (0.52 to 0.79) for 380 variants of LDL cholesterol level lowering. Conclusion Low LDL cholesterol levels due to PCSK9 and HMGCR variants had no causal effect on high risk of Alzheimer’s disease, vascular dementia, any dementia, or Parkinson’s disease; however, low LDL cholesterol levels may have a causal effect in reducing the risk of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCSK9 loss of function mutations carriers are at neutral risk of developing AD (86, 100, 101)”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is no consensus for an association between PCSK9 genetic variants and AD”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some genetic studies suggest that PCSK9 loss-of-function variants confer protection against AD, whereas others show no association.”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Mendelian randomization studies—which test whether genetically determined changes in PCSK9 influence disease susceptibility—have generally suggested that PCSK9 is unlikely to be a causal determinant of AD [23].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis based on the Mendelian randomization approach in the Danish population enrolled in two different prospective studies evidenced no causal effects of PCSK9 genetic variants on the risk of AD and also of other forms of dementia and Parkinson’s disease [123].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [123]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, genetic analyses—including GWAS and Mendelian randomization—generally failed to identify a causal link between PCSK9 and disease risk [23,25,26].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“However, the relationship between PCSK9 and AD is still largely unknown, as genetic studies have given opposite indications of the association between PCSK9 variants and AD predisposition [8,9,10].”
From PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer’s disease (2022) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, preclinical work alternately supports pro-amyloidogenic effects, negligible impact, or even context-dependent neuroprotection.”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“Examples of exposure sets where multivariable Mendelian randomization has been used include lipid fractions (such as high-density lipoprotein cholesterol, LDL-cholesterol, and triglycerides) 82 , and body composition measures (such as fat mass and fat-free mass) 83 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Flagged first, then by citations
Research works printed but not linked: 2
- [26]Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 2012; 9: e1001212 10.1371/journal.pmed.1001212 pmid:22563304. 22563304 PMC3341326 · DOI
- [35]Instrumental variables and GMM: estimation and testing. Stata J 2003; 3: 1- 33.
Cited by
Sorted by citations
Items 101–178 of 178
Impact of metabolic dysfunction on cognition in humans
Rasmussen, I. J., Thomassen, J. Q., & Frikke‐Schmidt, R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000723 · Cited by 14
Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran.
Saedi, S., Hemmati-Dinarvand, M., Barmaki, H., Mokhtari, Z., Musavi, H., Valilo, M., Mota, A., & Mahjoub, S. (2021) · PubMed Central · doi:10.22088/cjim.12.2.155 · Cited by 14
Microtubule affinity regulating kinase 4: A promising target in the pathogenesis of atherosclerosis
Qin, Y., Li, H., Wang, S., Wang, Z., & Tang, C. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30530 · Cited by 15
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
Şener, Y. Z., & Tokgözoğlu, L. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01918-2 · Cited by 13
Davidson, M. H., Szarek, M., Scheltens, P., Vijverberg, E., Hsieh, A., Ditmarsch, M., Kling, D., Curcio, D., Nicholls, S. J., Ray, K. K., et al. (2026) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100394 · Cited by 16
Grasset, L., Smit, R. A. J., Caunca, M. R., Elfassy, T., Odden, M. C., van der Grond, J., van Buchem, M. A., Stott, D. J., Sattar, N. A., Trompet, S., et al. (2020) · Journal of Aging and Health · doi:10.1177/0898264320916959 · Cited by 13
Novel therapeutic approaches for Parkinson’s disease by targeting brain cholesterol homeostasis
Pingale, T. D., & Gupta, G. L. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa063 · Cited by 12
Zhu, F.-L., Zhang, N., Ma, X., Yang, J., Sun, W., Shen, Y., Wen, Y., Yuan, S., Zhao, D., Zhang, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38298-5 · Cited by 13
Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
Wu, C., Wu, L., Wang, J., Lin, L., Li, Y., Lu, Q. L., & Deng, H.-W. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12148 · Cited by 13
Gao, Y., Zhao, P., Wang, C., Fang, K., Pan, Y., Zhang, Y., Miao, Z., Wang, M., Wei, M., Zou, W., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155844 · Cited by 12
Xiao, Q., Xi, J., Wang, R., Zhao, Q., Liang, X., Wu, W., Zheng, L., Guo, Q., Hong, Z., Fu, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.823406 · Cited by 11
Kuniholm, M. H., Liang, H., Anastos, K., Gustafson, D., Kassaye, S., Nowicki, M. J., Sha, B. E., Pawlowski, E., Gange, S. J., Aouizerat, B. E., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001648 · Cited by 11
Huang, Q., Zhang, Q., & Cao, B. (2024) · Brain and Behavior · doi:10.1002/brb3.3543 · Cited by 9
Sanluca, C., Spagnolo, P., Mancinelli, R., Bartolo, M. I. D., Fava, M., Maccarrone, M., Carotti, S., Gaudio, E., Leuti, A., & Vivacqua, G. (2024) · Metabolites · doi:10.3390/metabo14070352 · Cited by 9
Gene-environment interaction and Mendelian randomisation
Kolber, P. L., & Krüger, R. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.04.010 · Cited by 12
Lohoff, F. W. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy087 · Cited by 10
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
Nordestgaard, L. T., Hanson, A., Sanderson, E. C. M., Anderson, E. L., Walker, V. M., Tybjærg‐Hansen, A., Smith, G. D., & Nordestgaard, B. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70638 · Cited by 12
Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study
Zhao, Y., & Taliun, S. A. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.940118 · Cited by 9
New agents to reduce cholesterol levels: implications for nephrologists
Vecchio, L. D., Baragetti, I., & Locatelli, F. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz013 · Cited by 9
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Takechi, R., Sharif, A., Brook, E., Majimbi, M., Chan, D. C., Lam, V., Watts, G. F., & Mamo, J. C. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127481 · Cited by 10
Gianazza, E., Macchi, C., Banfi, C., & Ruscica, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1191303 · Cited by 10
Systematic review of Mendelian randomization studies on antihypertensive drugs
Fan, B., Zhang, J., & Zhao, J. V. (2024) · BMC Medicine · doi:10.1186/s12916-024-03760-x · Cited by 9
Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors
Balakrishna, A. M., Kaushik, S., Tandalam, S., Monther, N., Ponamgi, S., Alla, V. M., & Patil, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134562 · Cited by 8
Miki, A., Kinno, R., Ochiai, H., Kubota, S., Mori, Y., Futamura, A., Sugimoto, A., Kuroda, T., Kasai, H., Yano, S., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.667215 · Cited by 6
Hazzouri, A. Z. A., Jawadekar, N., Grasset, L., Kaiser, P., Kezios, K., Calónico, S., Glymour, M. M., Hirsch, C. H., Arnold, A. M., Varadhan, R., et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab220 · Cited by 7
Song, H., Lv, A., Zhu, Z., Li, R., Zhao, Q., Yu, X., Jiang, J., Lin, X., Zhang, C., Li, R., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae334 · Cited by 6
Kuller, L. H. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.011 · Cited by 6
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 6
So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors
Gencer, B., & Mach, F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx742 · Cited by 6
Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508292 · Cited by 6
Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View
Sarno, A. D., Romano, F., Arianna, R., Serpico, D., Lavorgna, M., Savastano, S., Colao, A., & Somma, C. D. (2025) · Metabolites · doi:10.3390/metabo15040282 · Cited by 5
Environmental and genetic risk factors for Parkinson's disease
Belbasis, L., Bellou, V., & Evangelou, E. (2020) · Diagnosis and Management in Parkinson's Disease · doi:10.1016/b978-0-12-815946-0.00004-1 · Cited by 1
Sarkar, S., Roy, D., Chatterjee, B., & Ghosh, R. (2024) · Metabolomics · doi:10.1007/s11306-024-02100-7 · Cited by 6
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang, Y., Wang, Y., Wang, Y., Ke, T., & Zhao, L. (2024) · PeerJ · doi:10.7717/peerj.17676 · Cited by 6
Atherogenic lipoproteins as treatment targets
Catapano, A. L. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.221 · Cited by 5
Precision health in Alzheimer disease: Risk assessment‐based strategies
Azar, J., Salama, M., Chidambaram, S. B., Al‐Balushi, B., Essa, M. M., & Qoronfleh, M. W. (2021) · Precision Medical Sciences · doi:10.1002/prm2.12036 · Cited by 7
Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000460 · Cited by 5
Suswidiantoro, V., Puteri, M. U., Kato, M., Ariestanti, D. M., James, R. J., & Saputri, F. C. (2025) · Life · doi:10.3390/life15121851 · Cited by 4
“This heterogeneity highlights the need for a comprehensive and critical synthesis of the available evidence [20,23].”
Zhu, X., Xu, Y., Li, L., Sun, J., Wang, Y., Chen, J., Wang, C., Zhang, S., & Jin, L. (2024) · Drug Development Research · doi:10.1002/ddr.22131 · Cited by 5
Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player
Alanazi, M., Al‐kuraishy, H. M., Hussain, N. R., Waheed, H. J., Al-Gareeb, A. I., Albuhadily, A. K., Waheeb, T. S., & Batiha, G. E. (2026) · Drug Development Research · doi:10.1002/ddr.70231 · Cited by 4
Benn, M., Emanuelsson, F., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf009 · Cited by 4
Self-citationTargeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Les germanies als Paîsos Catalans
Duran, E. (1982) · Dialnet (Universidad de la Rioja) · Cited by 4
Guo, X., Gao, F., Pan, B., Gao, F., Zhang, J., Wang, S., & Niu, Q. (2024) · Archives of Medical Science · doi:10.5114/aoms/192049 · Cited by 3
Pierzchlińska, A., Sławek, J. W., Kwaśniak-Butowska, M., Malinowski, D., Komaniecka, N., Mak, M., Czerkawska, A., Kukowka, A., & Białecka, M. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168964 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Association of genetic predisposition to dyslipidemia and physical activity with incident dementia
Liang, Y., Xie, S., Sheng, D., Ding, L., Yang, T., & Jia, J. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71079 · Cited by 2
Li, X., Jiang, F., Dong, Q., Chen, H., Ji, H., Dayimu, A., Yu, Y., Li, G., Li, N., Fu, P., et al. (2026) · Sensory Neuroscience · doi:10.1002/sen2.70019 · Cited by 2
Zuo, M., & Taliun, S. A. G. (2026) · BMC Neurology · doi:10.1186/s12883-026-04907-4 · Cited by 2
Lee, L., Walker, R. M., & Whiteley, W. N. (2022) · F1000Research · doi:10.12688/f1000research.121604.1 · Cited by 5
So, H., Chau, C. K., & Zhao, K. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170241 · Cited by 2
Lin, Y., Hu, T., Cheng, L., Chen, Y., Li, W., Guo, Q., & Miao, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230159 · Cited by 3
Belloso, R. D., Martín‐Bórnez, M., Macías‐García, D., García‐Díaz, S., Bonilla‐Toribio, M., Buiza‐Rueda, D., Sánchez, R. P., Muñoz‐Delgado, L., Ojeda–Ruiz, E., Jesús, S., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13404-6 · Cited by 1
Kelly, R. K., Harris, K., Muntner, P., & Woodward, M. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045533 · Cited by 1
Brain, benefit, or burden? Revisiting statins and cognitive function in older adults
Liu, Y., & Kunutsor, S. K. (2026) · GeroScience · doi:10.1007/s11357-026-02259-y · Cited by 1
Cholesterol metabolism in neurodegenerative diseases: mechanisms and therapeutic advances
Tu, D., Zheng, Y., Ding, P., Shen, M., Tang, W., Wei, B., & Wang, H. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00951-3 · Cited by 1
Wu, C., Wu, L., Wang, J., Lin, L., Li, Y., Lu, Q. L., & Deng, H. (2020) · medRxiv · doi:10.1101/2020.07.14.20153726 · Cited by 1
Genetic Variants for LDL Cholesterol and Risks for Alzheimer Disease and Parkinson Disease
Molano, J. R. V. (2017) · Journal watch · doi:10.1056/nejm-jw.na44002
Geistige Fähigkeiten nehmen nicht ab
bs (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-9820-1
Low LDL cholesterol levels may reduce risk of Alzheimer’s
Sander, R. (2017) · Nursing Older People · doi:10.7748/nop.29.8.11.s13
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Systematic review of Mendelian randomization studies on Parkinson’s disease
Kappen, S., Bottigliengo, D., Caliebe, A., Fabiola Del Greco, M., & König, I. R. (2022) · Medizinische Genetik · doi:10.1515/medgen-2022-2139
Shen, L., Yang, Y., Li, Y., Chin, H. L., Huang, H. Y. R., Cheung, B. M. Y., Tse, G., Chou, O. H. I., & Zhou, J. (2024) · medRxiv · doi:10.1101/2024.01.14.24301288
Saleh, A., & Esievo, K. A. N. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i2.6399
Zhang, X., Hu, W., Wang, Y., Wang, W., Liao, H., Zhang, X., Kiburg, K., Shang, X., Bulloch, G., Huang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488704
Unravelling the benefits of nutraceutical seaweed Ecklonia to reaping its pharmaceutical approaches
Venkatachalapathi, S., Balasubramanian, B., Bhotla, H. K., & Mahomoodally, M. F. (2025) · Natural Resources for Human Health · doi:10.53365/nrfhh/203180
Choe, Y. M., Choi, H., Keum, M., Lee, B. C., Suh, G., Kim, S. G., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2025) · Nutrients · doi:10.3390/nu17142321
Xie, Y., Zhao, L., Gao, L.-J., Xu, R., Gao, Y., Dou, K.-F., Yuanlin, G., & He, Y.-M. (2022) · Figshare · doi:10.6084/m9.figshare.21559156
Zhang, X., Hu, W., Wang, Y., Wang, W., Liao, H., Zhang, X., Kiburg, K., Shang, X., Bulloch, G., Huang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488701
Guo, X., Yu, J., Wang, R., Peng, N., & Li, R. (2024) · Figshare · doi:10.6084/m9.figshare.25376136
Low-density lipoprotein (LDL) in serum and measures of well-being
Koshino, A., & Hara, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28842-5.00017-x
Gu, T. F., Chen, Y. C., Zhang, N. X., Alam, U., Proietti, R., Liu, T., Chen, K., & Lip, G. Y. H. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70687
Gau, S.-Y., Lo, S., HSU, C., Tu, Y.-F., Su, Y.-J., Chen, C.-C., Wu, M.-C., Mitsukura, Y., & Chang, H.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1942691
Metadata
- Authors
- Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Benn, Marianne
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2017-04-24
- Volume
- 357
- Pages
- j1648
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- PMC
- PMC5421439
- OpenAlex
- W2607529696
- Cited by
- 178
- References
- 49
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 23 · 2020: 22 · 2019: 18 · 2018: 22 · 2017: 10
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-29)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Gentofte Hospital
- Herlev Hospital
- Lundbeckfonden (R126-2012-12556, R211-2015-3977)
- Danmarks Frie Forskningsfond
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- low LDL cholesterol, PCSK9, HMGCR, Alzheimer's disease, Parkinson's disease, vascular dementia, dementia, LDL cholesterol metabolism, genetic variants
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Alzheimer Disease, Denmark, Female, Follow-Up Studies, Genotype, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Parkinson Disease, Prospective Studies, Genetic Variation, Biomarkers, Proportional Hazards Models, Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
